Compare 8x8 Inc (EGHT) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Tempus AI — how do they compare? 8x8 Inc trades at $2.12 (market cap $311.98M), while Tempus AI trades at $71.21 (market cap $12.58B). The key difference: Tempus AI is far larger — about 40.3× 8x8 Inc's market cap, and Tempus AI is more actively traded (7,444,569 versus 1,639,086). Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Tempus AI for 23 Days on average.
| EGHT | TEM | |
|---|---|---|
Market Cap | $311.98M | $12.58B |
Volume | 1,639,086 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.76 | $99.28 |
52-Week Low | $1.59 | $41.55 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $578.90M | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21 million in 2025 despite revenue of $715.07 million, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights cost-saving wins for clients and AI product growth, with a consensus analyst price target of $19.77 suggesting significant upside potential from current levels.
The outlook hinges on the company's ability to translate top-line growth into sustained profitability. While valuation multiples like a P/S of 0.42 appear attractive, a high P/E of 72 and substantial long-term debt of $338.37 million present risks. The primary opportunity is execution on its financial model to achieve positive net income, as projected for 2026.
Tempus AI (TEM) trades at $71.46, up 1.66% with a bullish technical signal despite negative profitability metrics. The stock shows strong analyst support with 9 buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and 13 ESMO Congress presentations highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist at -$254M.
Outlook remains cautiously optimistic given strong institutional backing and AI healthcare growth potential, but profitability challenges and insider selling present near-term risks. The stock's valuation appears stretched with P/S of 8.61 and P/B of 28.27, requiring sustained revenue acceleration to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
